Recursion Pharmaceuticals (NASDAQ: RXRX) — Company Overview, News & Financial Data
Recursion Pharmaceuticals revolutionizes drug discovery using AI, focusing on developing therapies for diseases with unmet medical needs.
Recursion Pharmaceuticals
Recursion Pharmaceuticals (NASDAQ:RXRX) is at the forefront of integrating computational biology and artificial intelligence to revolutionize drug discovery and development. Operating out of its base, the company pioneers in utilizing its proprietary technology to decode biology and generate an ever-expanding set of data. These efforts aim to tackle some of the most challenging problems in life sciences, with a focus on uncovering novel therapeutics for a broad spectrum of diseases. Its projects span from early-stage drug discovery to advanced clinical trials, emphasizing the acceleration of the entire drug development process. Recursion's primary objective is to leverage its cutting-edge technology platform to speed up the discovery of treatments for diseases with unmet medical needs, potentially transforming the landscape of pharmaceuticals and healthcare.
Snapshot
Operations
Products and/or services of Recursion Pharmaceuticals
- A platform utilizing proprietary AI and machine learning to decode biological data for drug discovery and development.
- RE-0001819, a novel small molecule in phase 1 for the treatment of familial adenomatous polyposis.
- Digital chemistry platform designed to enhance and speed up the process of new drug creation through computation.
- Partnership with Bayer focusing on fibrotic diseases, employing machine learning to identify new therapeutic targets.
- Collaboration with Roche to harness artificial intelligence for drug discovery and development in neuroscience.
- Development of a scalable, cloud-based bioinformatics infrastructure to process and analyze biological and chemical data.
Recursion Pharmaceuticals executive team
- Najat KhanCEO, President & Director
- Ben R. TaylorCFO & President of Recursion UK
- Benjamin MabeyChief Technology Officer
- David HallettChief Scientific Officer
- Nathan HatfieldChief Legal Officer & Corporate Secretary
- Ryan KellyChief Communications Officer
- Erica FoxChief People and Impact Officer
- Matthew KinnChief Business Officer
- Sid JainSenior Vice President of Clinical Development & Data Science
- Vicki L. GoodmanChief Medical Officer
Latest news about Recursion Pharmaceuticals
Key financials
Reported results for Recursion Pharmaceuticals, in USD.
- Market cap
- 2.2B
- Revenue (TTM)
- 54.9M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.9
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 74.7M | -648.1M | -644.8M | |
| 58.8M | -479M | -463.7M | |
| 43.9M | -350.1M | -328.1M | |
| 39.7M | -245.7M | -239.4M |